NCT05252741
Unknown
Not Applicable
Evaluation Of Levels Of Pigment Epithelium-Derived Factor (PEDF) In Patients With Psoriasis.
ConditionsPsoriasis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Psoriasis
- Sponsor
- Sohag University
- Enrollment
- 52
- Locations
- 1
- Primary Endpoint
- changes in serum and tissue levels of (PEDF) in patients with psoriasis
- Last Updated
- 4 years ago
Overview
Brief Summary
Psoriasis is an immune-mediated chronic inflammatory skin disease associated with increase interaction of inflammatory mediators like adipokines. Pigment epithelium-derived factor (PEDF) is one of the most abundant adipokines and have anti-angiogenesis effect. There is a study showed that PEDF level is up-regulated in the sera of psoriasis patients.
Investigators
Omnia Ahmed Abdelhafez
Resident of Dermatology, Venereology and Andrology Sohag General Hospital
Sohag University
Eligibility Criteria
Inclusion Criteria
- •Patients with psoriasis and group of age and sex-matched healthy volunteers will be included as a control group.
Exclusion Criteria
- •Pregnancy.
- •Patients with other inflammatory skin disorders.
- •Patients on antioxidants or anti-inflammatory drugs.
- •Patients on topical or systemic treatment for psoriasis in the last 4 weeks prior to enrollment in the study.
- •Patients on systemic retinoids (Acitretin).
- •Obesity: body mass index (BMI ) \>
- •Malignancies e.g squamous cell carcinoma.
- •Viral warts.
- •Diabetes.
- •Hypertension.
Outcomes
Primary Outcomes
changes in serum and tissue levels of (PEDF) in patients with psoriasis
Time Frame: 12 months
evaluate serum and tissue level of (PEDF) in patients with psoriasis.
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
Effect of Atopic Diathesis as Assessed by Serum Th1/Th2 Cytokine Profile on Clinical Manifestation of PsoriasisPsoriasisNCT00372580National Taiwan University Hospital110
Completed
Phase 3
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar InvolvementPsoriasisNCT04713592AbbVie174
Unknown
Not Applicable
Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in PsoriasisPsoriasisMetabolic SyndromeDepressionNCT01661127Pusan National University Hospital10
Completed
Phase 3
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease SymptomsPsoriasisNCT04435600AbbVie139
Completed
Not Applicable
Cytokines and Vascular Inflammation in PsoriasisVascular InflammationPsoriasisCoronary AtherosclerosisNCT02305953Innovaderm Research Inc.96